To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral blood mononuclear cells in treatment of critical limb ischemia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
50
Zhihui Dong
Shanghai, China
RECRUITINGmajor-amputation-free survival rate
Time frame: at 6 months
improvement on transcutaneous partial oxygen pressure
Time frame: at 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.